All Announcements
Weil’s Amicus Brief Helps Secure Sixth Circuit Decision in Favor of Survivors of Sexual Abuse
The Weil team consists of Securities Litigation Co-Head Caroline Zalka, Litigation partner Arianna Scavetti, and associates Allie Rose and Seth Massey.
Read MoreDaniel L. Stein joins Weil as Co-Head of White Collar Practice in New York
International law firm Weil, Gotshal & Manges LLP has announced that Daniel L. Stein has joined the Firm as Co-Head of the global White Collar Defense, Regulatory and Investigations practice, based in Weil’s New York office.
Read MoreWeil Advises CD&R on its Acquisitions of Atalian and OCS
As a result of the transactions, the two family-owned businesses will create a global facilities management platform with a presence in Europe and Asia-Pacific across cleaning, security, catering, and multi-technical services, among others.
Read MoreExecutive Compensation & Benefits Partner Regina L. Readling joins Weil in New York
International law firm Weil, Gotshal & Manges LLP announced that Regina L. Readling has joined the Firm as a partner in the Executive Compensation & Benefits practice, based in Weil’s New York office.
Read MoreWeil Advises Howden on its Acquisition of TigerRisk Partners
Weil is advising international insurance broking group Howden on its acquisition of TigerRisk Partners, a leading risk, capital and strategic advisor to the global insurance and reinsurance industries.
Read MoreWeil Advises on $6.3B Debt Restructuring of Nordic Aviation Capital
The world’s largest regional aircraft lessor Nordic Aviation Capital (NAC) announced it successfully emerged from its pre-arranged U.S. Chapter 11 proceedings on June 1, 2022, concluding its $6.3 billion consensual debt restructuring.
Read MoreWeil Advised Halozyme Therapeutics, Inc. in its $960M Acquisition of Antares Pharma, Inc.
Weil advised Halozyme Therapeutics, Inc., a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies, in its $960 million acquisition of Antares Pharma, Inc., a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas.
Read More